hrp0097p2-83 | Growth and Syndromes | ESPE2023

Therapeutic compliance in 100 children treated with growth hormone

Iabbassen Malek , Bensalah Meriem , Haffaf Lounes , Bouchenna Amira , Khadidja Ouldkablia Samia

Context: The outcome of a treatment depends largely on the observance and compliance of the patient. Studies analyzing therapeutic compliance in chronic endocrine diseases are rare and especially controversial in childhood. Studies have reported poor adherence in 6-50% of cases.Patients and Methods: We studied treatment compliance in 100 children treated with subcutaneous growth hormone for growth hormone deficiency, int...

hrp0097p1-98 | GH and IGFs | ESPE2023

Evaluation of patients with growth hormone deficiency during the transition period

Bensalah Meriem , Iabbassen Malek , Haffaf Lounes , Bouchenna Amira , Lachkhem Aicha , Yahi Abdelkader , Sellal Zoubir , Medjaher Meriem , Khadidja Ouldkablia Samia

Introduction: The transition period between childhood and adulthood in patients with growth hormone deficiency is a vulnerable period during the follow-up. Different consensuses have established follow-up and reassessment protocols for this period in order to clarify whether GHD persists. The benefits of maintaining treatment during this period are widely documented on the metabolic, vascular, bone and in terms of quality of life and well-being.<p class="a...

hrp0094p2-340 | Multisystem endocrine disorders | ESPE2021

Follow-up and management of endocrine and metabolic disorders after hematopoietic stem cell transplantation in a patient followed for Fanconi anemia

Lassoued Najoua , Salem Houda Ben , Ayadi Younes , Hmida Nada , Zantour Baha , Alaya Wafa , Habib Sfar Mohamed ,

Introduction: Fanconi anemia (FA) is a very rare, complex and chronic genetic disorder. The diagnosis is most often made at pediatric age. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for bone marrow failure. FA on its own as well as its treatment can affect the endocrine system. We report the case of a child followed for 12 years after HSCT for FA.Observation: A patient has been followed since the age of...

hrp0094p2-342 | Multisystem endocrine disorders | ESPE2021

Combined pituitary hormone deficiency associated with Graves’ disease

Lassoued Najoua , Salem Houda Ben , Ayadi Younes , Kooli Mariem , Alaya Wafa , Habib Sfar Mohamed ,

Introduction: Graves’ disease is a common etiology of hyperthyroidism. The association of Graves’ disease and idiopathic combined pituitary hormone deficiency (ICPHD) is rare. We report the case of a patient followed for ICPHD who developed Graves’ disease during follow-up.Observation: A 13-year-old patient consults for stature delay. She had a family history of idiopathic hypogonadotropic hypogonadism in a 25-year-old bro...

hrp0094p2-345 | Multisystem endocrine disorders | ESPE2021

Endocrine manifestations in familial neurofibromatosis type 1: a case report

Ayadi Younes , Lassoued Najoua , Arfa Sondos , Kooli Mariem , Alaya Wafa , Sfar Mohamed Habib ,

Introduction: Type 1 neurofibromatosis (NF1), also called Recklinghausen’s disease, is one of the most common genetic diseases. It is autosomal dominant inherited. Its diagnosis is based on the presence of a familial history of NF1 in a first-degree relative and on the presence of a set of clinical arguments. Endocrine manifestations may exist. The most common are pheochromocytoma and precocious puberty, but other endocrine disorders can be observed more ...

hrp0092p1-215 | GH and IGFs (1) | ESPE2019

Acromesomelic Dysplasia, Type Maroteaux (AMDM): Impact of Long-term (8 years) High-dose Growth Hormone Treatment on Growth Velocity and Final Height in Two Siblings

Arya Ved Bhushan , Raj Meena , Kapoor Ritika R , Chapman Simon A , Younes Maha , Irving Melita , Buchanan Charles R

Introduction: Acromesomelic dysplasia, type Maroteaux (AMDM) is a rare autosomal recessive skeletal dysplasia, characterized by severe dwarfism and disproportionate shortening of the extremities, predominantly affecting middle and distal limb segments. It results from loss-of-function mutations affecting the C-type natriuretic peptide (CNP) receptor (NPR-B), a transmembrane guanylyl cyclase receptor encoded by the NPR2 gene. Resistance to growth hormo...